Researchers at Albert Einstein College of Medicine reported a new manufacturing strategy that generates longer-lived CAR‑T cells by linking IL‑7, IL‑15 and IL‑21 into a single protein scaffold (HCW9206). The study, published in Science Advances, shows the engineered cells are enriched for T memory stem cells and deliver sustained disease control in mouse models of blood cancer and HIV. The lead sentence: the team demonstrated a modular cytokine-fusion approach that increases CAR‑T cell self‑renewal and persistence compared with standard activation protocols. The paper names Harris Goldstein, MD, and collaborators and provides preclinical evidence supporting translation to clinical manufacturing workflows; T memory stem cells are a long-lived phenotype associated with durable responses and self-renewal. For readers: T memory stem cells (Tscm) are a subset of T cells that combine stem-like self-renewal with effector potential, relevant to prolonging adoptive cell therapy benefits.